{"id":"gp-combined-with-camrelizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, thrombocytopenia, neutropenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Nephrotoxicity (cisplatin-related)"}]},"_chembl":{"chemblId":"CHEMBL4297715","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine and cisplatin are cytotoxic chemotherapy agents that damage DNA and induce apoptosis in rapidly dividing cancer cells. Camrelizumab is a humanized monoclonal antibody that blocks PD-L1, removing the inhibitory signal that tumors use to evade immune attack, thereby restoring T-cell-mediated anti-tumor immunity. The combination leverages both direct cytotoxicity and immunotherapy synergy.","oneSentence":"GP (gemcitabine/cisplatin chemotherapy) combined with camrelizumab (a PD-L1 inhibitor) works by killing cancer cells directly while simultaneously unleashing immune responses against tumors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:13.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Likely advanced or metastatic solid tumors (specific indication under phase 3 evaluation not definitively confirmed in public sources)"}]},"trialDetails":[{"nctId":"NCT06669611","phase":"PHASE3","title":"Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-27","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":242},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT05772208","phase":"PHASE3","title":"Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":459},{"nctId":"NCT05742750","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-01","conditions":"Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GP Combined With Camrelizumab","genericName":"GP Combined With Camrelizumab","companyName":"XIANG YANQUN","companyId":"xiang-yanqun","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP (gemcitabine/cisplatin chemotherapy) combined with camrelizumab (a PD-L1 inhibitor) works by killing cancer cells directly while simultaneously unleashing immune responses against tumors. Used for Likely advanced or metastatic solid tumors (specific indication under phase 3 evaluation not definitively confirmed in public sources).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}